Aristea Kalikaki

686 total citations
9 papers, 589 citations indexed

About

Aristea Kalikaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Aristea Kalikaki has authored 9 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Aristea Kalikaki's work include Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Peptidase Inhibition and Analysis (2 papers). Aristea Kalikaki is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Peptidase Inhibition and Analysis (2 papers). Aristea Kalikaki collaborates with scholars based in Greece. Aristea Kalikaki's co-authors include Vassilis Georgoulias, Alexandra Voutsina, John Souglakos, Dimitris Mavroudis, Efstathios N. Stathopoulos, Maria Trypaki, Anastasios Koutsopoulos, D. Mavroudis, Maria Tzardi and Chara Papadaki and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

Aristea Kalikaki

9 papers receiving 580 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aristea Kalikaki Greece 7 374 369 222 184 94 9 589
B. E. Johnson United States 12 388 1.0× 359 1.0× 209 0.9× 101 0.5× 36 0.4× 17 534
M.P. López-Cabrerizo Spain 7 414 1.1× 404 1.1× 144 0.6× 105 0.6× 72 0.8× 8 577
F. Cardenal Spain 8 632 1.7× 585 1.6× 416 1.9× 202 1.1× 96 1.0× 26 946
Christine M. Parseghian United States 13 151 0.4× 402 1.1× 122 0.5× 228 1.2× 222 2.4× 52 531
R. Metzger United States 4 234 0.6× 360 1.0× 300 1.4× 106 0.6× 114 1.2× 4 612
Lingzhi Hong United States 12 238 0.6× 216 0.6× 213 1.0× 115 0.6× 34 0.4× 28 487
V. Gorbounova Russia 3 397 1.1× 359 1.0× 124 0.6× 95 0.5× 46 0.5× 7 516
Antonella Flacco Italy 9 482 1.3× 381 1.0× 269 1.2× 179 1.0× 67 0.7× 13 623
Rinat Galiulin United States 6 388 1.0× 370 1.0× 135 0.6× 110 0.6× 39 0.4× 7 556
Chihiro Dohi Japan 12 132 0.4× 285 0.8× 168 0.8× 301 1.6× 62 0.7× 17 502

Countries citing papers authored by Aristea Kalikaki

Since Specialization
Citations

This map shows the geographic impact of Aristea Kalikaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aristea Kalikaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aristea Kalikaki more than expected).

Fields of papers citing papers by Aristea Kalikaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aristea Kalikaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aristea Kalikaki. The network helps show where Aristea Kalikaki may publish in the future.

Co-authorship network of co-authors of Aristea Kalikaki

This figure shows the co-authorship network connecting the top 25 collaborators of Aristea Kalikaki. A scholar is included among the top collaborators of Aristea Kalikaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aristea Kalikaki. Aristea Kalikaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Koinis, Filippos, Alexandra Voutsina, Aristea Kalikaki, et al.. (2017). Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Clinical & Translational Oncology. 20(2). 140–149. 2 indexed citations
2.
Kalikaki, Aristea, Alexandra Voutsina, Anastasios Koutsopoulos, et al.. (2015). ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Cancer Investigation. 33(4). 107–113. 12 indexed citations
3.
Kalikaki, Aristea, John Souglakos, Stella Apostolaki, et al.. (2014). KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer. PLoS ONE. 9(8). e104902–e104902. 36 indexed citations
4.
Voutsina, Alexandra, Maria Tzardi, Aristea Kalikaki, et al.. (2012). Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Modern Pathology. 26(2). 302–313. 50 indexed citations
5.
Saridaki, Zacharenia, Maria Tzardi, Chara Papadaki, et al.. (2011). Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. PLoS ONE. 6(1). e15980–e15980. 101 indexed citations
7.
Kalikaki, Aristea, et al.. (2009). DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 10(2). 118–123. 129 indexed citations
8.
Kalikaki, Aristea, Anastasios Koutsopoulos, Dora Hatzidaki, et al.. (2009). Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 69(1). 110–115. 76 indexed citations
9.
Kalikaki, Aristea, Anastasios Koutsopoulos, Maria Trypaki, et al.. (2008). Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British Journal of Cancer. 99(6). 923–929. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026